

Madrid, February 19, 2026

LABIANA HEALTH, S.A. (hereinafter, the "Company"), in compliance with the provisions of Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of April 16, 2014, on market abuse, and in accordance with the provisions of Article 227 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, on information to be provided by companies listed on that segment, hereby makes public the following:

INSIDE INFORMATION

Agreement to execute a capital increase

The Company's Board of Directors, acting under the authorization granted by the Ordinary General Shareholders' Meeting held on June 26, 2025, under item 7 of its agenda, has agreed, at its meeting held on February 18, 2026, to execute a capital increase for a maximum effective amount of €5,072,000 (the "**Capital Increase**").

The Capital Increase will be carried out through the issuance and circulation of up to 1,268,000 new ordinary shares of the Company, which will be issued at a unit issue price (par value plus issue premium) of €4 per share, to be paid up in full through cash contributions.

The funds obtained from the Capital Increase will be used to finance investments in plant and working capital.

It is also reported that no Market Expansion Document (DAM) is being submitted for this transaction, given that the shares issued as a result of the Capital Increase represent less than 30% of the number of shares of the same class already listed on BME Growth, and no other capital increases have been carried out in the last twelve months.

The new shares will be issued with recognition of the preemptive subscription rights of the Company's shareholders (other than the Company itself) who have acquired their shares up to 11:59 p.m. (CET) on the day of publication of the announcement of the Capital Increase in the Official Gazette of the Mercantile Registry, inclusive, and whose transactions have been settled within the two business days immediately following (the "**Legitimate Shareholders**").

Each share of the Company currently in circulation will entitle the holder to receive one preemptive subscription right. Eligible Shareholders may exercise their preemptive subscription rights in the proportion of 10 new shares for every 55 shares of the Company currently in circulation that they hold.

The subscription rights shall be transferable under the same conditions as the shares from which they derive, in accordance with the provisions of Article 306.2 of the Spanish Companies Act (), and their trading will be requested on the BME Growth segment of BME MTF Equity ("**BME Growth**") during the last six business days of the Preemptive Subscription Period.

Preferential subscription period (first round)

The period during which Eligible Shareholders may exercise their preemptive subscription rights (the "**Preemptive Subscription Period**") shall begin on the day following the publication of the Capital Increase agreement in the Official Gazette of the Mercantile Registry and shall end after 14 calendar days.

During the Preemptive Subscription Period, the Company's shareholders and those investors who have acquired preemptive subscription rights and are interested in subscribing for New Shares must contact the entity participating in Iberclear or the participating entities in whose accounting records such securities are registered, indicating their willingness to exercise, in whole or in part, their preemptive subscription rights. Requests made in relation to the exercise of preemptive subscription rights shall be understood to be final, irrevocable, and unconditional and shall entail the subscription of new shares.

During the Preemptive Subscription Period, Eligible Shareholders who have exercised all of their preemptive subscription rights and investors who acquire preemptive subscription rights and exercise them in full may request, at the time of exercising such rights, the subscription of additional shares ("**Additional Shares**") in the event that at the end of the Preemptive Subscription Period there are new shares that have not been subscribed ("**Surplus Shares**").

Unexercised preemptive subscription rights will automatically expire at the end of the Preemptive Subscription Period.

Additional share allocation period (second round)

In the event that, at the end of the Preemptive Subscription Period, there are Remaining Shares, a process for the allocation of additional shares will be opened in which the Remaining Shares will be distributed among the Eligible Shareholders and the investors who have requested the subscription of Additional Shares.

If the number of Additional Shares requested exceeds the Remaining Shares, the agent designated for this purpose by the Company will pro rata the allocation in accordance with the following rules:

- i. The Remaining Shares will be allocated in proportion to the volume of Additional Shares requested, using the percentage that the number of Additional Shares requested by each applicant represents in relation to the total Additional Shares requested. The number of Additional Shares to be delivered will be determined by applying this percentage to the total Remaining Shares, rounded down to the nearest whole number.
- ii. Any Remaining Shares that remain unallocated as a result of rounding will be allocated, one by one, to each applicant for Additional Shares, starting with the applicant who has requested the largest number of Additional Shares, followed by the next applicant in descending order of the number of Additional Shares requested, until all Remaining Shares have been allocated.
- iii. In the event of a tie in the number of Remaining Shares requested, allocation will be made in alphabetical order by surname or company name.

Discretionary allocation period (third round)

If, at the end of the Preemptive Subscription Period and the additional share allocation period, there are still new shares that have not been subscribed (hereinafter, the difference between

the total number of New Shares and the sum of those subscribed during the Preemptive Subscription Period and the additional share allocation period, the "**Discretionary Allocation Shares**"), a discretionary allocation period for those shares (the "**Discretionary Allocation Period**") will begin, during which they may be allocated to those persons who express their interest in subscribing for and paying for them to the Company.

The Discretionary Allocation Period shall commence on the day following the commencement of the additional share allocation period and shall last for five calendar days, without prejudice to the Company's right to extend or terminate it at any time.

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its administrators.

We remain at your disposal for any clarifications you may require.

Sincerely,

Mr. Manuel Ramos Ortega
Chief Executive Officer
LABIANA HEALTH, S.A.